Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives

Drug, Healthcare and Patient Safety

Volumn 1, Issue 1, 2009, Pages 35-45

  Lu, Zhengwu ^a  

^a ABBOTT VASCULAR   (United States)

Author keywords

Adverse drug reaction; Adverse event; Information technology; Pharmacovigilance; Risk management; Safety; Standard

Indexed keywords

DECISION SUPPORT SYSTEM; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; INFORMATION TECHNOLOGY; MEDICAL INFORMATICS; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT;

EID: 73249128697     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/dhps.s7180     Document Type: Review

References (21)

1. WHO Collaborating Centre for International Drug Monitoring. The Importance of Pharmacovigilance - Safety Monitoring of Medicinal Products. Geneva, Switzerland: World Health Organization; 2002.
2. FDA Clinical Medical. Guidance for Industry - Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. Rockville, MD: US Food and Drug Administration; 2005.
3. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28:851-870.
4. Bobo R, Notte J. Safety reporting in clinical trials. Next Generation Pharmaceutical. Available from: http://www.ngpharma.com/pastissue/article. asp?art=26377&issue=159. Accessed August 22, 2009.
5. Spink C. Pharmaceutical Clinical Development: Realising the full rewards of Electronic Data Capture (EDC). IBM Global Services March 2002. Available from:http://www-935.ibm.com/services/uk/igs/pdf/esr-pharmaceutical-clinincal- development-realising-the-full-rewardsof-edc.pdf. Accessed October 6, 2009.
6. Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmacovigilance. Drug Saf. 2005;28:981-1007.
7. Nelson RC, Palsulich B, Gogolak V. Good pharmacovigilance practices: Technology enabled. Drug Saf. 2002;25:407-414.
8. Lindquist M. VigiBase. The WHO Global ICSR Database System: Basic facts. Drug Inf J. 2008;42:409-419.
9. World Health Organization. WHO Programme for International Drug Monitoring. Available from: http://www.who-umc.org/DynPage.aspx?id= 13140&mn=1514. Accessed on August 22, 2009.
10. Mann RD, Andrews EB (editors). Pharmacovigilance. Chichester, NH: John Wiley & Sons Ltd; 2002.
11. Avorn J, Schneeweiss S. Managing drug-risk information: What to do with all those new numbers. N Engl J Med. 2009;361:647-649.
12. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 2002;25:381-392.
13. Sundström A, Hallberg P. Data mining in pharmacovigilance - detecting the unexpected: the role of index of suspicion of the reporter. Drug Saf. 2009;32:419-427.
14. Clinical Data Interchange Standards Consortium (CDISC); CDASH Core and Domain Teams. Clinical Data Acquisition Standards Harmonization (CDASH). Austin, TX: Clinical Data Interchange Standards Consortium; October 2008.
15. Buetow K. Building a 21st Century Biomedical System: the cancer biomedical informatics grid (caBIG®). Philadelphia, PA: Annual Meeting of DIA Data Conference; March 9-11, 2009.
16. Hochberg AM, Hauben M. Time-to-signal comparison for drug safety data-mining algorithms vs traditional signaling criteria. Clin Pharmacol Ther. 2009;85:600-606.
17. Hauben M, Aronson JK. Defining "signal" and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf. 2009;32:99-110.
18. Klein DF, O'Brien CP. Improving detection of adverse effects of marketed drugs. JAMA. 2007;298:333-334.
19. Alemenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82:157-166.
20. Hauben M, Aronson JK. Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high grade ore. Drug Saf. 2007;30:645-655.
21. US Food and Drug Administration. The Sentinel Initiative: A National Strategy for Monitoring Medical Product Safety, May 2008. Available from: http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm089474.htm. Accessed October 6, 2009.